Charter Renewal for the Advisory Committee on Infant Mortality, 52514 [2019-21439]
Download as PDF
<![CDATA[
khammond on DSKJM1Z7X2PROD with NOTICES
52514
Federal Register / Vol. 84, No. 191 / Wednesday, October 2, 2019 / Notices
functional studies of cold stored
platelets, clinical studies, and the
potential role of cold stored platelets in
clinical care in military and civilian
patient populations. The committee will
also discuss the clinical studies needed
to support the indications for use of
cold stored platelet products stored
beyond 3 days.
FDA intends to make background
material available to the public no later
than 2 business days before the meeting.
If FDA is unable to post the background
material on its website prior to the
meeting, the background material will
be made publicly available at the
location of the advisory committee
meeting, and the background material
will be posted on FDA’s website after
the meeting. Background material is
available at https://www.fda.gov/
AdvisoryCommittees/Calendar/
default.htm. Scroll down to the
appropriate advisory committee meeting
link. For those unable to attend in
person, the meeting will also be
webcast; please see the following link
for webcast and other meeting
information: https://www.fda.gov/
advisory-committees/blood-productsadvisory-committee/2019-meetingmaterials-blood-products-advisorycommittee.
Procedure: On November 22, 2019,
from 8:30 a.m. to 4:45 p.m., the meeting
is open to the public. Interested persons
may present data, information, or views,
orally or in writing, on issues pending
before the committee. Written
submissions may be made to the contact
person on or before November 13, 2019.
Oral presentations from the public will
be scheduled between approximately
2:35 p.m. and 3:35 p.m. Those
individuals interested in making formal
oral presentations should notify the
contact person and submit a brief
statement of the general nature of the
evidence or arguments they wish to
present, the names and addresses of
proposed participants, and an
indication of the approximate time
requested to make their presentation on
or before November 4, 2019. Time
allotted for each presentation may be
limited. If the number of registrants
requesting to speak is greater than can
be reasonably accommodated during the
scheduled open public hearing session,
FDA may conduct a lottery to determine
the speakers for the scheduled open
public hearing session. The contact
person will notify interested persons
regarding their request to speak by
November 5, 2019.
Persons attending FDA’s advisory
committee meetings are advised that the
Agency is not responsible for providing
access to electrical outlets.
VerDate Sep<11>2014
16:42 Oct 01, 2019
Jkt 250001
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with disabilities.
If you require accommodations due to a
disability, please contact Christina Vert
(see FOR FURTHER INFORMATION CONTACT)
at least 7 days in advance of the
meeting.
FDA is committed to the orderly
conduct of its advisory committee
meetings. Please visit our website at:
https://www.fda.gov/Advisory
Committees/AboutAdvisoryCommittees/
ucm111462.htm for procedures on
public conduct during advisory
committee meetings.
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
Dated: September 26, 2019.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
[FR Doc. 2019–21399 Filed 10–1–19; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Services
Administration
Charter Renewal for the Advisory
Committee on Infant Mortality
Health Resources and Services
Administration (HRSA), Department of
Health and Human Services (HHS).
ACTION: Notice.
AGENCY:
represents a public-private partnership
at the highest level to provide guidance
and focus attention on the policies and
resources required to address the
reduction of infant mortality and the
improvement of the health status of
pregnant women and infants. With a
focus on life course, the Committee also
addresses disparities in maternal health
to improve maternal health outcomes,
including preventing and reducing
maternal mortality and severe maternal
morbidity. The Committee also provides
advice on how best to coordinate the
myriad of federal, state, local, and
private programs and efforts that are
designed to deal with the health and
social problems impacting infant
mortality and maternal health.
The charter renewal for ACIM was
approved on September 30, 2019, which
also stands as the filing date. Renewal
of the ACIM charter gives authorization
for the Committee to operate until
September 30, 2021. A copy of the
ACIM charter is available on the ACIM
website at https://www.hrsa.gov/
advisory-committees/infant-mortality/
index.html. A copy of the charter also
can be obtained by accessing the FACA
database that is maintained by the
Committee Management Secretariat
under the General Services
Administration. The website address for
the FACA database is https://
www.facadatabase.gov/.
Maria G. Button,
Executive Secretariat.
[FR Doc. 2019–21439 Filed 10–1–19; 8:45 am]
BILLING CODE 4165–15–P
In accordance with the
Federal Advisory Committee Act, HHS
is hereby giving notice that the Advisory
Committee on Infant Mortality (ACIM or
the Committee) has been renewed.
DATES: The effective date of the charter
renewal is September 30, 2019.
FOR FURTHER INFORMATION CONTACT:
David S. de la Cruz, Ph.D., MPH,
Designated Federal Official (DFO),
HRSA, Maternal and Child Health
Bureau, 5600 Fishers Lane, 18N25,
Rockville, Maryland 20857; 301–443–
0543; or dcruz@hrsa.gov.
SUPPLEMENTARY INFORMATION: ACIM is
authorized by section 222 of the Public
Health Service Act (42 U.S.C. 217a), as
amended. The Committee is governed
by provisions of Public Law 92–463, as
amended, (5 U.S.C. App. 2), which sets
forth standards for the formation and
use of Advisory Committees. ACIM
advises the Secretary of HHS on
department activities and programs
directed at reducing infant mortality
and improving the health status of
pregnant women and infants. ACIM
SUMMARY:
PO 00000
Frm 00061
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Performance Review Board Members
Title 5, U.S.C. Section 4314(c)(4) of
the Civil Service Reform Act of 1978,
Public Law 95–454, requires that the
appointment of Performance Review
Board Members be published in the
Federal Register.
The following persons may be named
to serve on the Performance Review
Boards from 2019 to 2021, which
oversee the evaluation of performance
appraisals and compensation for Senior
Executive Service, Senior Level/Senior
Technical, and Title 42 executive
equivalent members of the Department
of Health and Human Services.
Last name
AGNEW .....................
ALEXANDER ............
ALVAREZ ..................
AMES ........................
E:\FR\FM\02OCN1.SGM
02OCN1
First name
ANN
THOMAS
JUAN CARLOS
KAREN
]]>Agencies
[Federal Register Volume 84, Number 191 (Wednesday, October 2, 2019)]
[Notices]
[Page 52514]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-21439]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Health Resources and Services Administration
Charter Renewal for the Advisory Committee on Infant Mortality
AGENCY: Health Resources and Services Administration (HRSA), Department
of Health and Human Services (HHS).
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: In accordance with the Federal Advisory Committee Act, HHS is
hereby giving notice that the Advisory Committee on Infant Mortality
(ACIM or the Committee) has been renewed.
DATES: The effective date of the charter renewal is September 30, 2019.
FOR FURTHER INFORMATION CONTACT: David S. de la Cruz, Ph.D., MPH,
Designated Federal Official (DFO), HRSA, Maternal and Child Health
Bureau, 5600 Fishers Lane, 18N25, Rockville, Maryland 20857; 301-443-
0543; or [email protected].
SUPPLEMENTARY INFORMATION: ACIM is authorized by section 222 of the
Public Health Service Act (42 U.S.C. 217a), as amended. The Committee
is governed by provisions of Public Law 92-463, as amended, (5 U.S.C.
App. 2), which sets forth standards for the formation and use of
Advisory Committees. ACIM advises the Secretary of HHS on department
activities and programs directed at reducing infant mortality and
improving the health status of pregnant women and infants. ACIM
represents a public-private partnership at the highest level to provide
guidance and focus attention on the policies and resources required to
address the reduction of infant mortality and the improvement of the
health status of pregnant women and infants. With a focus on life
course, the Committee also addresses disparities in maternal health to
improve maternal health outcomes, including preventing and reducing
maternal mortality and severe maternal morbidity. The Committee also
provides advice on how best to coordinate the myriad of federal, state,
local, and private programs and efforts that are designed to deal with
the health and social problems impacting infant mortality and maternal
health.
The charter renewal for ACIM was approved on September 30, 2019,
which also stands as the filing date. Renewal of the ACIM charter gives
authorization for the Committee to operate until September 30, 2021. A
copy of the ACIM charter is available on the ACIM website at https://www.hrsa.gov/advisory-committees/infant-mortality/. A copy of
the charter also can be obtained by accessing the FACA database that is
maintained by the Committee Management Secretariat under the General
Services Administration. The website address for the FACA database is
https://www.facadatabase.gov/.
Maria G. Button,
Executive Secretariat.
[FR Doc. 2019-21439 Filed 10-1-19; 8:45 am]
BILLING CODE 4165-15-P
